The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

centocor.com

Founded Year

1979

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Centocor

Centocor is a biotechnology company that was founded in 1979 with the initial goal of using monoclonal antibody technology to develop new diagnostic assays.On July 23, 1999, Centocor was acquired by Johnson & Johnson.

Centocor Headquarter Location

800/850 Ridgeview Drive

Horsham, Pennsylvania, 19044,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Centocor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Centocor is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Centocor Patents

Centocor has filed 70 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/22/2013

6/24/2014

Viral plant pathogens and diseases, Molecular biology, RNA, DNA, Potato cultivars

Grant

Application Date

3/22/2013

Grant Date

6/24/2014

Title

Related Topics

Viral plant pathogens and diseases, Molecular biology, RNA, DNA, Potato cultivars

Status

Grant

Latest Centocor News

Tazarotene, halobetasol combination efficacious in scalp psoriasis

Nov 18, 2021

Disclosures: Kircik reports receiving either grant or honoraria from Abbott Laboratories, AbbVie, Allergan Inc., Almirall, Amgen Inc., Arcutis, Biogen-Idec, BMS, Boehringer Ingelheim, Breckenridge Pharma, Celgene, Centocor Inc., Cellceutix, Cipher, CombiMatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dow Pharmaceutical Sciences Inc., Dr. Reddy’s Lab, Eli Lilly, Galderma, Genentech Inc., GlaxoSmithKline, PLC, Idera, Johnson & Johnson, Leo, Maruho, Merck, Medicis Pharmaceutical Corp., NovartisAG, Promius, PharmDerm, Pfizer, Serono (Merck Serono International SA), Stiefel Laboratories Inc., Sun Pharma, Taro, UCB, Valeant Pharmaceuticals Intl. and XenoPort. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Scalp psoriasis was improved with a fixed combination of tazarotene and halobetasol propionate lotion , according to an open-label pilot study. “About 80% of psoriasis patients have scalp involvement, which can be challenging to treat,” Elif Ozyurekoglu and Leon H. Kircik, MD, of the Ichan School of Medicine and Mount Sinai, wrote. “Fixed combination tazarotene 0.045% and halobetasol propionate 0.01% (Duobrii, Ortho Dermatologics) lotion has recently been approved for the treatment of moderate to severe plaque type psoriasis . The lotion base is suggested to confer benefits for application to the hair-bearing scalp.” A study found scalp psoriasis was improved with a fixed combination of tazarotene and halobetasol propionate lotion. The open-label, single-center pilot study included 21 patients (average age, 52 years; 57% men; 95% white) with moderate to severe plaque psoriasis, as defined by an Investigator Global Assessment (IGA) scale value of 3 or 4 with scalp involvement. Each patient was provided with the medication and instructed to apply the lotion to the affected areas once daily for 12 weeks. IGA scores were improved significantly at weeks 4, 8 and 12 with 10 (48%) patients reaching clear or almost clear status by week 8 (P = .0006). At week 12, 40% of subjects remained clear or almost clear (P = .004). Psoriasis scalp severity index (PSSI) 75 was achieved by 67% of patients at week 8, with 45% of patients maintaining PSSI 75 at week 12. PSSI 90 was achieved by 38% of subjects at week 8, with 30% maintaining at week 12. PSSI 100 was seen in 29% at week 8 with 20% maintaining at week 12. Scalp IGA of clear or almost clear was achieved by 15 (72%) patients at week 8 with 50% maintaining through week 12. In addition, 29% had a completely clear scalp at week 8, with 20% maintaining at week 12. There were no study-related adverse events. “Scalp psoriasis is a significant concern for affected patients, and treatment has remained challenging,” the authors wrote. “Results of this pilot study demonstrate that fixed combination tazarotene 0.045% and halobetasol propionate 0.01% lotion is efficacious for the treatment of scalp psoriasis in adults, based on significant improvements in IGA, PSSI, BSA, sIGA and DLQI.”

  • When was Centocor founded?

    Centocor was founded in 1979.

  • Where is Centocor's headquarters?

    Centocor's headquarters is located at 800/850 Ridgeview Drive, Horsham.

  • What is Centocor's latest funding round?

    Centocor's latest funding round is Acq - P2P.

  • Who are the investors of Centocor?

    Investors of Centocor include Johnson & Johnson, Massachusetts Institute of Technology, Bessemer Venture Partners, Canaan Partners and Venrock.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.